title: Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation.
abstract: Graft-versus-host disease (GVHD) remains a major obstacle to allogeneic bone marrow transplantation. We administered cyclosporin A (CsA) by continuous intravenous infusion for prophylaxis against GVHD and adjusted the dose to maintain a constant whole blood level. Forty-five patients, ranging in age from 16 to 56, mean 39.5 years, undergoing allogeneic transplantation for various hematological malignancies received CsA as a continuous intravenous infusion. CsA was started on day -1 and continued until day +22 when oral CsA was initiated. The whole blood level of CsA was determined and the dose adjusted to maintain a fixed level. Methotrexate 15 mg/m2 i.v. was given on day +1, followed by 10 mg/m2 on days +3 and +6. CsA administered as a continuous infusion was well tolerated. All patients required multiple adjustments of the infused dose of CsA to maintain the targeted whole blood level. The mean rise in creatinine was 0.89 mg/dl. There was an association between the concomitant administration of amphotericin B and CsA and the development of nephrotoxicity. Hypertension developed in 30/45 patients, and all responded to oral nifedipine. Tremors were noted in 16/45 patients. None of the patients developed serious neurological side effects. Greater than grade-I acute GVHD developed in only 13% of the patients. We conclude that administering CsA as an adjusted dose by continuous intravenous infusion is well tolerated and effective in preventing acute GVHD in patients undergoing allogeneic bone marrow transplantation.
authors.affiliation: New England Medical Center, Boston, MA 02111.
authors.forename: K B
authors.initials: KB
authors.lastname: Miller
authors.forename: D P
authors.initials: DP
authors.lastname: Schenkein
authors.forename: R
authors.initials: R
authors.lastname: Comenzo
authors.forename: J K
authors.initials: JK
authors.lastname: Erban
authors.forename: T
authors.initials: T
authors.lastname: Fogaren
authors.forename: C A
authors.initials: CA
authors.lastname: Hirsch
authors.forename: E
authors.initials: E
authors.lastname: Berkman
authors.forename: A
authors.initials: A
authors.lastname: Rabson
mesh_terms: D000293:Adolescent; D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control*; D006801:Humans; D007260:Infusion Pumps; D007262:Infusions, Intravenous; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011182:Postoperative Care; D014184:Transplantation, Homologous
chemical_list: D004338:Drug Combinations; D000666:Amphotericin B; D016572:Cyclosporine; D003404:Creatinine; D008727:Methotrexate